Get the Stockscreener App
2.49
4.62%
0.11
Cyclerion Therapeutics Inc stock is traded at $2.49, with a volume of 9,342.
It is up +4.62% in the last 24 hours and down -21.94% over the past month.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
See More
Previous Close:
$2.38
Open:
$2.34
24h Volume:
9,342
Relative Volume:
0.27
Market Cap:
$8.31M
Revenue:
$556.00K
Net Income/Loss:
$-5.28M
P/E Ratio:
-1.1636
EPS:
-2.14
Net Cash Flow:
$-6.23M
1W Performance:
+5.73%
1M Performance:
-21.94%
6M Performance:
-11.70%
1Y Performance:
-4.23%
1-Day Range:
$2.33
$2.55
1-Week Range:
$2.30
$2.5899
52-Week Range:
$1.27
$9.4699
Cyclerion Therapeutics Inc Stock (CYCN) Company Profile
Name
Cyclerion Therapeutics Inc
Sector
Industry
Phone
617-621-7722
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare CYCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYCN
Cyclerion Therapeutics Inc
|
2.49 | 9.04M | 556.00K | -5.28M | -6.23M | -2.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclerion Therapeutics Inc Stock (CYCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-21 | Initiated | Truist | Buy |
| Sep-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-03-19 | Initiated | Credit Suisse | Neutral |
Cyclerion Therapeutics Inc Stock (CYCN) Latest News
How to forecast Cyclerion Therapeutics Inc. trends using time seriesWeekly Gains Report & Entry Point Strategy Guides - Newser
Cyclerion Therapeutics Inc. stock outlook for YEARCPI Data & Low Volatility Stock Recommendations - Newser
Candlestick signals on Cyclerion Therapeutics Inc. stock todayNew Guidance & Smart Allocation Stock Reports - Newser
Analyzing net buyer seller activity in Cyclerion Therapeutics Inc.Portfolio Update Summary & Free Weekly Watchlist of Top Performers - Newser
Understanding Cyclerion Therapeutics Inc.’s price movementMarket Rally & Long-Term Growth Stock Strategies - Newser
Applying Wyckoff theory to Cyclerion Therapeutics Inc. stockJuly 2025 Fed Impact & Consistent Profit Alerts - Newser
Will Cyclerion Therapeutics Inc. Recover After Recent DeclineJuly 2025 Recap & Safe Swing Trade Setups - thegnnews.com
Chart based exit strategy for Cyclerion Therapeutics Inc.Quarterly Portfolio Review & Reliable Volume Spike Trade Alerts - Newser
How Cyclerion Therapeutics Inc. stock performs during market volatility2025 Investor Takeaways & Community Consensus Trade Signals - Newser
What’s the recovery path for long term holders of Cyclerion Therapeutics Inc.Market Risk Report & Low Volatility Stock Recommendations - Newser
Quantitative breakdown of Cyclerion Therapeutics Inc. recent moveJuly 2025 Update & High Accuracy Swing Entry Alerts - Newser
What recovery options are there for Cyclerion Therapeutics Inc.Quarterly Portfolio Review & Advanced Swing Trade Entry Plans - Newser
Cognitive Impairment Associated with Schizophrenia Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | CAutifony Therapeutics, Cyclerion Therapeutics, Biogen - Barchart.com
Top chart patterns to watch in Cyclerion Therapeutics Inc.2025 Bull vs Bear & Stock Portfolio Risk Control - Newser
Key resistance and support levels for Camp4 Therapeutics CorporationMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Published on: 2025-08-19 06:42:44 - news-j.co.kr
Institutional scanner results for Cyclerion Therapeutics Inc.Earnings Performance Report & Precise Swing Trade Entry Alerts - Newser
Will Cyclerion Therapeutics Inc. rebound enough to break even2025 AllTime Highs & Weekly High Return Opportunities - Newser
How to build a dashboard for Cyclerion Therapeutics Inc. stockWeekly Risk Report & Risk Controlled Daily Plans - Newser
Cyclerion Therapeutics Inc. stock chart pattern explained2025 Pullback Review & AI Forecasted Entry/Exit Points - Newser
Can machine learning forecast Cyclerion Therapeutics Inc. recoveryGold Moves & Low Drawdown Momentum Trade Ideas - Newser
Using data tools to time your Cyclerion Therapeutics Inc. exitPortfolio Risk Summary & Real-Time Chart Pattern Alerts - Newser
Will Cyclerion Therapeutics Inc. outperform the marketJuly 2025 Review & Technical Pattern Alert System - Newser
Heatmap analysis for Cyclerion Therapeutics Inc. and competitorsJuly 2025 Weekly Recap & Capital Efficiency Focused Strategies - Newser
Does Cyclerion Therapeutics Inc. show high probability of reboundQuarterly Investment Review & Free Reliable Trade Execution Plans - Newser
What’s the recovery path for long term holders of MIRA Pharmaceuticals Inc.Trend Reversal & Accurate Entry/Exit Alerts - Newser
Using portfolio simulators with Cyclerion Therapeutics Inc. includedExit Point & Momentum Based Trading Ideas - Newser
Is Cyclerion Therapeutics Inc. showing signs of accumulation2025 Trading Recap & Verified Swing Trading Watchlists - Newser
Cyclerion Therapeutics Inc Stock (CYCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):